University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States
NCT Number: NCT03380156
Heart failure (HF) is the leading cause of hospitalization in the US. Endothelial dysfunction, characterized by the decreased vasodilatory capacity of the vascular endothelium, is rampant in atherosclerotic diseases such as coronary artery disease and also in HF. Endothelial dysfunction also correlates with HF severity, progression, and mortality. It is postulated that endothelial dysfunction may in part be due to enhanced sympathetic drive, diminished parasympathetic drive, chronic inflammatory state thereby leading to reduced nitric oxide synthase activity in the vascular endothelium. Low-level vagus nerve stimulation (LLVNS) is an invasive way to modulate autonomic tone. Recent experimental and clinical data suggest that low-level transcutaneous vagal stimulation (TVS) (by stimulating the auricular branch of the vagus nerve located at the tragus of the external ear) may produce the same desired neuromodulator effect compared to LLVNS. The objective of this study is to determine the impact of TVS on endothelial dysfunction and arterial stiffness. The study population will include patients with chronic HFrEF. After performing baseline flow-mediated dilation (FMD), laser speckle contrast imaging(LSCI) and pulse wave analysis (PWA) testing, patients will be randomized to TVS or sham stimulation with a crossover design at different time points. The patient randomized to TVS arm will undergo stimulation for 1 hour followed by immediate measurement of FMD,LSCI and PWA. There will be a washout period of at least 24 hours with patient crossing over to the other arms thus serving as their self-control.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Oklahoma City, Oklahoma, 73117, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
Time frame: Change from baseline to post stimulation(within 10 minutes) with TVNS/Sham stimulation
Flow mediated vasodilatation will be tested. A change in the maximal diameter of the brachial artery(in mm) will be assessed before and within 10 minutes of TVNS/sham stimulation.
Time frame: Change from baseline to post stimulation(within 15-20 minutes) with TVNS/Sham stimulation
Arterial elasticity. Augmentation pressure (AP) will be calculated which is expressed as a percentage of the aortic pulse pressure (PP) which is the difference of systolic and diastolic BP(mm Hg).
Time frame: Change from baseline to post stimulation(within 30 minutes) with TVS/Sham stimulation
LSCI based perfusion index will be calculated before and within 30 minutes of TVS or sham stimulation
University of Oklahoma
Other
Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in Patients With Heart Failure With Reduced Ejection Fraction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04539093
Endothelial Dysfunction, Heart Failure With Reduced Ejection Fraction
Milwaukee, Wisconsin, United States
View Trial DetailsNCT06576297
Aging, Frailty
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07697365
Cardiovascular Diseases, Chronic Heart Failure
Athens, Attica, Greece
View Trial DetailsNCT07599345
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction
Boston, Massachusetts, United States
View Trial Details